Published in AIDS on June 19, 2007
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa | NCT02060162
Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) (ADEPTT) | NCT03302299
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med (2012) 2.05
Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings. J Acquir Immune Defic Syndr (2015) 1.48
Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One (2009) 1.43
Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One (2013) 1.35
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J (2008) 1.30
Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS (2010) 1.27
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis (2009) 1.26
Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis (2011) 1.20
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One (2011) 1.17
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis (2008) 1.17
Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med (2013) 1.01
Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS (2010) 1.00
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One (2012) 0.97
Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep (2011) 0.97
Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J (2012) 0.95
HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther (2010) 0.95
Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci (2011) 0.92
Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS (2007) 0.92
Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test. PLoS One (2013) 0.90
Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. Curr HIV/AIDS Rep (2015) 0.89
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health (2010) 0.89
Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. Int J STD AIDS (2012) 0.87
Problem of hepatocellular carcinoma in West Africa. World J Hepatol (2014) 0.86
Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf (2011) 0.85
Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia. Ethiop J Health Sci (2013) 0.84
Hepatitis B virus / human immunodeficiency virus co-infection and its hepatocarcinogenic potential in sub-saharan black africans. Hepat Mon (2012) 0.83
Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients. PLoS One (2014) 0.83
Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. BMC Infect Dis (2016) 0.83
Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol (2012) 0.83
Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health (2008) 0.82
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol (2012) 0.80
A point-of-care paper-based fingerstick transaminase test: toward low-cost "lab-on-a-chip" technology for the developing world. Clin Gastroenterol Hepatol (2013) 0.80
Implementation of routine screening for chronic hepatitis B virus co-infection by HIV clinics in Lusaka, Zambia. J Viral Hepat (2015) 0.80
Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. Antivir Ther (2013) 0.80
Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature. BMC Infect Dis (2012) 0.78
PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics (2016) 0.77
Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South Africa. PLoS One (2015) 0.77
Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. PLoS One (2016) 0.77
Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes. Redox Biol (2014) 0.77
Elevated alanine aminotransferase in antiretroviral-naïve HIV-infected African patients: magnitude and risk factors. HIV Med (2012) 0.76
Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS. PLoS One (2016) 0.76
Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals. Med J Armed Forces India (2017) 0.75
Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma. Niger Med J (2016) 0.75
Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection. J Glob Infect Dis (2016) 0.75
Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study. AIDS Res Treat (2016) 0.75
Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. BMC Infect Dis (2017) 0.75
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med (2007) 6.26
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet (2006) 5.98
Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis (2009) 5.75
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr (2006) 4.81
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 4.62
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 4.07
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med (2011) 3.46
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis (2007) 3.23
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis (2002) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis (2013) 2.95
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86
Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr (2009) 2.81
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr (2006) 2.77
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS (2010) 2.60
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis (2004) 2.44
Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis (2008) 2.42
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis (2010) 2.38
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS (2010) 2.33
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis (2012) 2.30
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS (2007) 2.23
From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med (2007) 2.23
Confronting multidrug-resistant tuberculosis. N Engl J Med (2012) 2.22
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.21
Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis (2013) 2.15
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA (2007) 2.13
Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials (2007) 2.12
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med (2007) 2.08
HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med (2009) 2.07
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature (2009) 2.05
Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A (2008) 2.03
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ (2010) 2.03
HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis (2010) 2.02
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96